Company intelligence / Profile preview

SEMNL

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Semnal Bio is an early-stage biotechnology company focused on developing a novel class of therapeutics based on signal-dependent protein degradation. The company's platform technology aims to selectively degrade disease-causing proteins only when specific cellular signals are present, potentially increasing therapeutic precision and reducing off-target effects. By leveraging the cell's natural signaling pathways, Semnal Bio seeks to address targets that have previously been considered undruggable. The company is currently advancing its internal pipeline with a primary focus on oncology and immunological disorders.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeProteolysis-targeting chimera therapy
Industry: Biotech

Beyond the preview

Go deeper on SEMNL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SEMNL.

Explore the full profile